4.8 Article

LAMP-Seq enables sensitive, multiplexed COVID-19 diagnostics using molecular barcoding

Journal

NATURE BIOTECHNOLOGY
Volume 39, Issue 12, Pages 1556-+

Publisher

NATURE PORTFOLIO
DOI: 10.1038/s41587-021-00966-9

Keywords

-

Funding

  1. Deutsche Forschungsgemeinschaft (DFG) [EXC2151 -390873048]
  2. DFG [GE 976/9-2, LU1944/3-1]
  3. Federal Ministry for Education and Research [01KX2021]
  4. Klarman Incubator
  5. National Institutes of Health [1R01-HG009761, 1R01-MH110049, 1DP1-HL141201]
  6. Harold G. and Leila Mathers Foundation
  7. Patrick J. McGovern Foundation
  8. Open Philanthropy Project
  9. Poitras Center for Psychiatric Disorders Research at MIT
  10. Hock E. Tan and K. Lisa Yang Center for Autism Research at MIT
  11. Phillips family
  12. Howard Hughes Medical Institute
  13. Howard Hughes Medical Institute Gilliam Fellowship
  14. Edward Mallinckrodt, Jr. Foundation

Ask authors/readers for more resources

Frequent and fast testing with high sensitivity and specificity, low cost, and easy deployment make LAMP-Seq a promising tool for integrated public health surveillance programs in containing COVID-19 outbreaks.
Frequent testing of large population groups combined with contact tracing and isolation measures will be crucial for containing Coronavirus Disease 2019 outbreaks. Here we present LAMP-Seq, a modified, highly scalable reverse transcription loop-mediated isothermal amplification (RT-LAMP) method. Unpurified biosamples are barcoded and amplified in a single heat step, and pooled products are analyzed en masse by sequencing. Using commercial reagents, LAMP-Seq has a limit of detection of similar to 2.2 molecules per mu l at 95% confidence and near-perfect specificity for severe acute respiratory syndrome coronavirus 2 given its sequence readout. Clinical validation of an open-source protocol with 676 swab samples, 98 of which were deemed positive by standard RT-qPCR, demonstrated 100% sensitivity in individuals with cycle threshold values of up to 33 and a specificity of 99.7%, at a very low material cost. With a time-to-result of fewer than 24 h, low cost and little new infrastructure requirement, LAMP-Seq can be readily deployed for frequent testing as part of an integrated public health surveillance program.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.8
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available